UBS Maintains Buy on Legend Biotech, Raises Price Target to $49

Benzinga Newsdesk www.benzinga.com Positive 83.4%

Neg 0% Neu 0% Pos 83.4%

UBS analyst Ashwani Verma maintains Legend Biotech (NASDAQ:LEGN) with a Buy and raises the price target from $31 to $49.